Roche's Tecentriq Intravenous Cancer Therapy Gets UK Approval
29 Agosto 2023 - 4:51AM
Noticias Dow Jones
By Giulia Petroni
Roche said the U.K.'s medicines regulator has approved its
Tecentriq intravenous cancer therapy.
The Swiss pharmaceutical company said Tuesday that the therapy
will be available to patients for all indications in which the
formulation has been previously approved, including certain types
of lung, bladder, breast and liver cancer.
Tecentriq SC is Roche's fourth subcutaneous cancer therapy.
The approval granted by the U.K. Medicines and Healthcare
products Regulatory Agency is the first for Tecentriq SC globally.
Evaluations by the U.S. Food and Drug Administration and other
health authorities are currently underway, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 29, 2023 05:36 ET (09:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Roche Holdings Ltd AG (QX) (OTCMarkets): 0 recent articles
Más de Roche Holdings Ltd AG (QX) Artículos de Noticias